ConCallIQ
Go Pro
DRREDDY Diversified 23 Jan 2026

Dr. Reddy's Laboratories Limited — Q3 FY26

Dr.

neutral medium
Compare with...
Revenue ₹8,753 Cr +4.4%
EBITDA ₹2,049 Cr -11%
PAT ₹1,190 Cr -14%
EBITDA Margin 22% -401bps
Duration
Read Time 1 min read

✓ Verified against BSE filing

Delivery score0%
Due this quarter1
Delivered0
Missed1

Indian management teams deliver on roughly 12% of specific earnings-call promises. A low score does not indicate dishonesty — it reflects how aspirational forward guidance typically is.

Q2 FY26

Abatacept BLA submission by end of December 2025

BLA for abatacept IV will be submitted by end of calendar 2025, with high confidence in approval.

Missed

Current-quarter commentary contains related risk or weakness, so the promise appears not to have been delivered yet.

heuristic_v1